XPR – Lifestyle Demo
Author:
BioInvent International
BioInvent’s TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)
May 12, 2026
BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026
May 12, 2026
Resolutions at BioInvent’s Annual General Meeting 2026
April 29, 2026
BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio
April 29, 2026
BioInvent International AB: Interim Report January – March 2026
April 29, 2026
BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting
April 21, 2026
BioInvent International AB Publishes Annual Report 2025
March 31, 2026
BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis
March 26, 2026